Sapana Verma, Subhash Gupta – 10 November 2018

Leticia Muñoz, María‐José Borrero, María Úbeda, Elisa Conde, Rosa del Campo, Macarena Rodríguez‐Serrano, Margaret Lario, Ana‐María Sánchez‐Díaz, Oscar Pastor, David Díaz, Laura García‐Bermejo, Jorge Monserrat, Melchor Álvarez‐Mon, Agustín Albillos – 10 November 2018 – In cirrhosis, intestinal dysbiosis, intestinal barrier impairment, and systemic immune system abnormalities lead to gut bacterial translocation (GBT) and bacterial infection. However, intestinal immune system dysfunction and its contribution to barrier damage are poorly understood.

This program discusses different, yet related, basic molecular mechanisms of hepatic damage and inflammation fundamental for the development of various types of liver diseases. Discussions will cover the mechanisms for vesicle formation and  endocytosis, how secretion of exosomes occurs upon inflammasome activation, the impact of immune cell-derived vesicles on fibrosis and the process of collagen secretion. The second part of the program focuses on novel signaling pathways  involved in disease resolution.

There has been no new drug class in the treatment of portal hypertension in over 25 years. But recent advancements in our understanding of the pathophysiology of portal hypertension and its potential regression have informed development of oninvasive biomarkers and revealed exciting new targets for therapy.

This workshop will look at various training pathways for a career in hepatology. It will also describe various career opportunities in research, practice, education and industry, providing an overview of the rewards and challenges for each of these, and identify sources for research funding for fellows and junior faculty members.Oren K. Fix Dr. Oren Fix is the Medical Director of the Liver Transplant Program at Swedish Medical Center in Seattle, Washington, Clinical Associate Professor at the Washington State University Elson S.

Bacterial infections are common in patients with advanced cirrhosis — partly related to altered microbiota, partly related to increased bacterial translocation across the gut wall and partly related to compromised immune function of these patients. When bacterial infection occurs, the heightened inflammatory reaction that follows predisposes these patients to altered hemodynamics and direct tissue damage. Therefore, these patients are prone to develop organ failure and ACLF when bacterial infection occurs.

This program presents an update on the current state of knowledge about autoimmune hepatitis and identify the gaps in knowledge related to the immunologic, environmental, and genetic factors underlying AIH. The program will also review clinical management, identify unmet needs, and discuss barriers along the path toward development of new therapies for AIH.Christopher L. Bowlus (Moderator) Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr.

The hemodynamic changes in Fontan circulation (the palliative intervention in single ventricle physiology) confer risk of liver complications, particularly congestive hepatopathy. This program will include descriptions of the hepatopathy, the pathobiology of Fontan associated liver fibrosis, available diagnostic tools including imaging techniques and transplant-related medical decision making in the context of a failing Fontan.Veena Venkat Angela Lorts Elizabeth Rand Jonathan Dillman Vijay Shah John Magee

This program will detail recent advances in the understanding of genetic and epigenetic alterations that influence NAFLD and its progression. It will emphasize their impact on the natural history of NAFLD and variability in clinical outcomes. Details on how patient based epigenetic association studies have led to novel insights into disease pathogenesis will be outlined with an emphasis on how this may translate to new therapeutics.

This program covers the key components that support efforts to define a program toward eradication of HCV in the U.S.  The program is centered around modeling, engagement of individuals difficult to link to care and screening efforts.  Access to care and the role of advocacy is instrumental and approaches toward successful advocacy will also be discussed.John W. Ward John W. Ward, MD created and directs the Coalition for Global Hepatitis Elimination of the Task Force for Global Health.